Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors

Fig. 2

EP13 inhibits mitochondrial respiration in MDA-MB-231, MCF-7, and Hs578T cells. a Chemical structures of TGZ, Δ2-TGZ, and EP13. b MDA-MB-231, MCF-7, and Hs578T cells were grown in 2D conditions and treated for 4 h with vehicle, TGZ (45 µM, 74 µM and 50 µM, respectively), Δ2-TGZ (60 µM, 60 µM and 50 µM, respectively) or EP13 (6 μM, 6 µM and 9 µM, respectively), and the OCR was measured using XFe24 Seahorse. Basal and maximal respiration are depicted as the mean ± S.D. of at least three independent measurements (*, p < 0.05). c Assessment of the OXPHOS parameters of the breast cancer cell lines. At the times indicated, the following drugs were injected: oligomycin A (Oligo; 2 µM), FCCP (1.1 µM and 2.2 µM), and rotenone/antimycin A (Rot/AA; 1 µM each). Data are the mean ± S.D. (at least n = 3 wells per group). d A typical Hs578T spheroid observed before the measurement of OXPHOS parameters. e Assessment of the OXPHOS parameters on Hs578T spheroids exposed to increasing concentrations of EP13. The results are depicted as the mean ± S.D. (at least n = 3 wells per group)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us